8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: July 25, 2014

(Date of earliest event reported)

REVA MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-54192	33-0810505
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

5751 Copley Drive, San Diego, CA	92111
(Address of principal executive offices)	(Zip Code)

(858) 966-3000

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

Dr. Alexandre Abizaid, Director of Invasive Cardiology at the Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, is presenting information on REVA Medical, Inc.’s (“REVA”) Fantom scaffold program on Friday, July 25, 2014 at 1:55 p.m. EDT at the Bioresorbable Vascular Scaffold Conference. The conference is being held July 25th and 26th at the Fairmont Copley Plaza in Boston, Massachusetts. The presentation materials being delivered are attached hereto as Exhibit 99.1. A copy of the materials will be posted under the Investor Relations section of REVA’s website at www.revamedical.com.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information including Exhibits 99.1 through 99.3, is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Item 9.01   Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.	Description
99.1	Presentation entitled, REVA’s Bioresorbable Scaffold Program Update.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	REVA Medical, Inc.
Date: July 25, 2014	/s/ Katrina L. Thompson
	Katrina L. Thompson
	Chief Financial Officer
	(principal financial and accounting officer)

3

Index to Exhibits

Exhibit Number	Description of Exhibits
99.1	Presentation entitled, REVA’s Bioresorbable Scaffold Program Update.

4

EX-99.1

Exhibit 99.1

 REVA’s Bioresorbable Scaffold Program Update Alexandre Abizaid, MD, PhD, FACC Instituto Dante Pazzanese de Cardiologia Sao Paulo, Brazil

REVA’s Technology Transition to the Fantom Scaffold 2011: ReZolve® Slide & Lock Platform Non-deformable design based upon slide & lock technology Currently being evaluated in 112 patients in the RESTORE II Study Preliminary results Acute technical success > 95% Uniform scaffolding with reduction in strut thickness desired to improve deliverability and laminar flow Clinical follow-up ongoing through 9-month primary endpoint 2014: REVA Transition to the Fantom™ Platform Designed to be deliverable, visible, strong, and easy to use

Fantom™ Sirolimus-Eluting Bioresorbable Scaffold

REVA Polymer Family High-performance biomaterials Based on phenyl ring structure Competitive Polymers Polylactide-based Based on Alkane structure Polymer Foundation for the Fantom Scaffold REVA Polymer Family vs. Competitive Polymers Phenyl ring structure provides high strength, radiopaque materials without compromising structural properties

Fantom Performance Targets vs. Competitive Polylactide-Based Scaffolds Attribute Fantom Performance Crossing profile + Reduced Profile (5 Fr) Radiopacity +++ Complete Scaffold Visibility Inflation performance ++ Single-Step Inflation Expansion Range ++ Large Expansion Range High Safety Margin Against Fracture Strength + Increase in Radial Strength Drug Elution = Equivalent with Reduced Dose Degradation time + Balancing Vessel Support with Return to Vasomotion Shipping and storage + Controlled Shipping Room Temp. Storage

Fantom Low Crossing Profile Effect of Strut Thickness on Crossing Profile A reduction in strut thickness of only 25-30 µm achieves >10% decrease in profile and significant improvements in deliverability PLLA Scaffold 1.4 mm (.055”) Fantom <1.27 mm (.050”) A Small Change has a Big Impact

Fantom Strut Thickness Decreased Strut Thickness without Compromise in Strength The design objective was to minimize strut thickness without sacrificing scaffold strength REVA’s polymer family has the properties to achieve this goal Decreased strut thickness enables reduced crossing profile Strut Thickness * Metal Drug-Eluting Stent

Fantom Bioresorbable Scaffold Radial Strength with Reduced Strut Thickness Advanced polymer properties enable reduced strut thickness

Fantom Bioresorbable Scaffold Radiopacity Fantom’s complete (x-ray) visibility increases confidence during the procedure Precise scaffold placement Complete lesion coverage No geographic miss Confirmation of apposition to vessel wall Reduces need for IVUS & OCT catheter use Saving costs to hospital No permanent metal markers required Absorb Fantom Xience

Fantom Bioresorbable Scaffold Inflation Performance & Expansion Range Single-step inflation directly to intended diameter No need for intermediate steps Post-dilation without compromise Substantial safety margin Large expansion range without the concern of fracture Able to adjust for vessel taper to meet vessel apposition needs 3.0mm Nominal Device Capable of expansion to >4.8mm without fracture 4.0 mm 4.5 mm 4.87 mm 3.0 mm

Fantom Bioresorbable Scaffold Single-Step Inflation REVA’s advanced polymer enables single-step inflation

Fantom Bioresorbable Scaffold Degradation & Resorption Degradation Greater than 80% degradation within 1 year Full restoration of natural vasomotion Eliminates undesirable shear stress induced by a permanent implant Resorption Complete resorption within ~3 years 0 10 20 30 40 50 60 70 80 90 100 0 2 4 6 8 10 12 Percentage Months Degradation Profile Molecular Weight Loss

Fantom Preclinical Results Angiographic, IVUS and OCT Images thru 3 months Visibility, conformability and maintenance of vessel patency Implant One Month Three Month

Fantom Preclinical Results Angiographic Visibility Complete visibility of the entire scaffold

Fantom Clinical Plan First Patient Implants anticipated Q4’14 All CE sites fully enrolling by early 2015 Up to 125 patients Over 20 clinical investigational centers AUS, BE, BR, DK, FR, DE, NL and PL Primary endpoints MACE and late lumen loss at six months

Fantom Bioresorbable Scaffold Overview Visibility Strength Ease-of-Use Improved deliverability with reduced profile Superior scaffold visibility Expansion with one smooth and continuous inflation No requirement for “stepped” inflation Post-dilation without compromise Scaffold strength to treat challenging lesions No procedural time limitations No special storage requirements Human Clinical Evaluation Q4 2014